Anti-monkeypox Drug Discovery Platforms
Online inquiry

We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.

* Name
* Phone
* Email
* Products or Services Interested
Project Description

Anti-monkeypox Drug Discovery Platforms

Creative Biolabs provides a proven and innovative one-stop solution for anti-monkeypox drug discovery. When working with us, there is no need to change providers, which can be time-consuming and expensive. You can count on our skilled and enthusiastic staff to find the most appropriate path that can make your drug discovery journey easier.

Overview of Anti-Monkeypox Drug Discovery

Most approved antiviral drugs target a viral enzyme that plays an essential role in virus replication. Viral (DNA or RNA) polymerases are highly successful drug targets. The successful development of antiviral drugs is highly dependent on close interaction and collaboration between chemists and biologists (biomedical). At present, almost all antiviral drugs used in clinical treatment target only specific viruses and their subunits. It is important to study virus-host interactions and to identify key cellular cofactors or signaling pathways that are commonly required by different viruses. With the increase in monkeypox cases worldwide, a better understanding of the monkeypox virus (MPXV) is important for accelerating the development of anti-monkeypox vaccines and drugs.

Anti-Monkeypox Drug Discovery Platforms at Creative Biolabs

The development of an effective antiviral drug is usually accompanied by the expansion of successful strategies through numerous chemical changes to improve parameters including affinity, toxicity, pharmacology, and resistance.

The selection of in vitro antiviral test systems that will provide selective, sensitive, and reproducible results is a priority in this anti-monkeypox drug discovery and development process. In vitro antiviral assays using cell-based systems commonly use inhibition of viral plaque formation, viral cytopathic effect (CPE), or viral hemagglutinin (HA) or other viral protein, with inhibition of virus yield used in follow-up evaluations.

Animal models allow for progress based on tissue culture assessment of antiviral efficacy. The evaluation of an antiviral, in the context of a host with a functioning immune system, enables a better understanding of therapeutics’ potential efficacy. Animal models are used for in vivo study of potential virus inhibitors with a variety of parameters used to indicate the severity of the infection and its inhibition by therapy.

Artificial intelligence (AI) and machine learning technology play a crucial role in drug discovery and development. AI algorithms are increasingly being applied for rapid and cost-effective drug discovery. Through the introduction of AI tools and network medicine, there are good opportunities for drug discovery and development.

High-throughput screening (HTS) has been used as an efficient tool in identifying new lead compounds for antiviral drug development. It provides starting chemical matter in the adventure of developing a new drug. HTS is simple, rapid, low-cost, and efficient, based on ligand-target interaction, and can obtain higher information.

Using real-time PCR as the gold standard, a variety of diagnostic methods for the detection of MPXV have been established with high sensitivity and specificity. A simple and easy molecular diagnostic method will improve MPXV detection and monitoring.

Methodical approach to antivirals design and biological evaluation.Fig.1 Methodical approach to antivirals design and biological evaluation. (Bugert, 2020)

At Creative Biolabs, we have the expertise to optimize every stage of drug discovery to ensure you get the results you want and achieve the highest level of efficiency. Our experts can help you from the very first idea, by providing expert consultancy in the design of your study. We are happy to discuss your objectives. Contact us to discuss your next anti-monkeypox drug discovery project.


  1. Bugert, J.J.; et al. Antivirals in medical biodefense. Virus Genes. 2020, 56(2): 150-167.

We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.